BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ. Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies. J Virol 2015;89:10982-92. [PMID: 26311869 DOI: 10.1128/JVI.01490-15] [Cited by in Crossref: 99] [Cited by in F6Publishing: 65] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE Jr, Andersen KG, Saphire EO, Ward AB. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol 2016;1:16128. [PMID: 27562261 DOI: 10.1038/nmicrobiol.2016.128] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 11.3] [Reference Citation Analysis]
2 Saphire EO, Schendel SL, Fusco ML, Gangavarapu K, Gunn BM, Wec AZ, Halfmann PJ, Brannan JM, Herbert AS, Qiu X, Wagh K, He S, Giorgi EE, Theiler J, Pommert KBJ, Krause TB, Turner HL, Murin CD, Pallesen J, Davidson E, Ahmed R, Aman MJ, Bukreyev A, Burton DR, Crowe JE Jr, Davis CW, Georgiou G, Krammer F, Kyratsous CA, Lai JR, Nykiforuk C, Pauly MH, Rijal P, Takada A, Townsend AR, Volchkov V, Walker LM, Wang CI, Zeitlin L, Doranz BJ, Ward AB, Korber B, Kobinger GP, Andersen KG, Kawaoka Y, Alter G, Chandran K, Dye JM; Viral Hemorrhagic Fever Immunotherapeutic Consortium. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell 2018;174:938-952.e13. [PMID: 30096313 DOI: 10.1016/j.cell.2018.07.033] [Cited by in Crossref: 111] [Cited by in F6Publishing: 98] [Article Influence: 37.0] [Reference Citation Analysis]
3 Dowall SD, Bosworth A, Rayner E, Taylor I, Landon J, Cameron I, Coxon R, Al Abdulla I, Graham VA, Hall G, Kobinger G, Hewson R, Carroll MW. Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic. Sci Rep 2016;6:30497. [PMID: 27465308 DOI: 10.1038/srep30497] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Cao L, Zhang L, Zhang X, Liu J, Jia MA, Zhang J, Liu J, Wang F. Types of Interferons and Their Expression in Plant Systems. J Interferon Cytokine Res 2022;42:62-71. [PMID: 35171703 DOI: 10.1089/jir.2021.0148] [Reference Citation Analysis]
5 Cui Q, Cheng H, Xiong R, Zhang G, Du R, Anantpadma M, Davey RA, Rong L. Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. Viruses 2018;10:E678. [PMID: 30513600 DOI: 10.3390/v10120678] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
6 Zhang M, Wang X, Hu L, Zhang Y, Zheng H, Wu H, Wang J, Luo L, Xiao H, Qiao C, Li X, Huang W, Wang Y, Feng J, Chen G. TIM-1 Augments Cellular Entry of Ebola Virus Species and Mutants, Which Is Blocked by Recombinant TIM-1 Protein. Microbiol Spectr 2022;:e0221221. [PMID: 35384693 DOI: 10.1128/spectrum.02212-21] [Reference Citation Analysis]
7 Chan M, Holtsberg FW, Vu H, Howell KA, Leung A, Van der Hart E, Walz PH, Aman MJ, Kodihalli S, Kobasa D. Efficacy of Ebola Glycoprotein-Specific Equine Polyclonal Antibody Product Against Lethal Ebola Virus Infection in Guinea Pigs. J Infect Dis 2018;218:S603-11. [PMID: 29955852 DOI: 10.1093/infdis/jiy329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
8 Carias LL, Dechavanne S, Nicolete VC, Sreng S, Suon S, Amaratunga C, Fairhurst RM, Dechavanne C, Barnes S, Witkowski B, Popovici J, Roesch C, Chen E, Ferreira MU, Tolia NH, Adams JH, King CL. Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein. J Immunol 2019;202:2648-60. [PMID: 30944159 DOI: 10.4049/jimmunol.1801631] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
9 Bazzill JD, Stronsky SM, Kalinyak LC, Ochyl LJ, Steffens JT, van Tongeren SA, Cooper CL, Moon JJ. Vaccine nanoparticles displaying recombinant Ebola virus glycoprotein for induction of potent antibody and polyfunctional T cell responses. Nanomedicine 2019;18:414-25. [PMID: 30471480 DOI: 10.1016/j.nano.2018.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
10 Nyakatura EK, Zak SE, Wec AZ, Hofmann D, Shulenin S, Bakken RR, Aman MJ, Chandran K, Dye JM, Lai JR. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. J Biol Chem 2018;293:6201-11. [PMID: 29500195 DOI: 10.1074/jbc.RA117.001627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
11 Fanunza E, Frau A, Corona A, Tramontano E. Antiviral Agents Against Ebola Virus Infection: Repositioning Old Drugs and Finding Novel Small Molecules. Annu Rep Med Chem 2018;51:135-73. [PMID: 32287476 DOI: 10.1016/bs.armc.2018.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Schmidt R, Beltzig LC, Sawatsky B, Dolnik O, Dietzel E, Krähling V, Volz A, Sutter G, Becker S, von Messling V. Generation of therapeutic antisera for emerging viral infections. NPJ Vaccines 2018;3:42. [PMID: 30323953 DOI: 10.1038/s41541-018-0082-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Hargreaves A, Brady C, Mellors J, Tipton T, Carroll MW, Longet S. Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application. Pathogens 2021;10:1201. [PMID: 34578233 DOI: 10.3390/pathogens10091201] [Reference Citation Analysis]
14 Murray LP, Govindan R, Mora AC, Munro JB, Mace CR. Antibody affinity as a driver of signal generation in a paper-based immunoassay for Ebola virus surveillance. Anal Bioanal Chem 2021;413:3695-706. [PMID: 33852053 DOI: 10.1007/s00216-021-03317-4] [Reference Citation Analysis]
15 Maskus DJ, Królik M, Bethke S, Spiegel H, Kapelski S, Seidel M, Addai-Mensah O, Reimann A, Klockenbring T, Barth S, Fischer R, Fendel R. Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. Sci Rep 2016;6:39462. [PMID: 28000709 DOI: 10.1038/srep39462] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
16 Rghei AD, van Lieshout LP, Santry LA, Guilleman MM, Thomas SP, Susta L, Karimi K, Bridle BW, Wootton SK. AAV Vectored Immunoprophylaxis for Filovirus Infections. Trop Med Infect Dis 2020;5:E169. [PMID: 33182447 DOI: 10.3390/tropicalmed5040169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Dash R, Das R, Junaid M, Akash MF, Islam A, Hosen SZ. In silico-based vaccine design against Ebola virus glycoprotein. Adv Appl Bioinform Chem 2017;10:11-28. [PMID: 28356762 DOI: 10.2147/AABC.S115859] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
18 Barolo L, Abbriano RM, Commault AS, George J, Kahlke T, Fabris M, Padula MP, Lopez A, Ralph PJ, Pernice M. Perspectives for Glyco-Engineering of Recombinant Biopharmaceuticals from Microalgae. Cells 2020;9:E633. [PMID: 32151094 DOI: 10.3390/cells9030633] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
19 Castelli M, Clementi N, Pfaff J, Sautto GA, Diotti RA, Burioni R, Doranz BJ, Dal Peraro M, Clementi M, Mancini N. A Biologically-validated HCV E1E2 Heterodimer Structural Model. Sci Rep 2017;7:214. [PMID: 28303031 DOI: 10.1038/s41598-017-00320-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
20 Steeds K, Hall Y, Slack GS, Longet S, Strecker T, Fehling SK, Wright E, Bore JA, Koundouno FR, Konde MK, Hewson R, Hiscox JA, Pollakis G, Carroll MW. Pseudotyping of VSV with Ebola virus glycoprotein is superior to HIV-1 for the assessment of neutralising antibodies. Sci Rep 2020;10:14289. [PMID: 32868837 DOI: 10.1038/s41598-020-71225-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Ahmad B, Ashfaq UA, Rahman MU, Masoud MS, Yousaf MZ. Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach. Microb Pathog 2019;132:243-53. [PMID: 31075428 DOI: 10.1016/j.micpath.2019.05.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
22 King B, Tarr AW. How have retrovirus pseudotypes contributed to our understanding of viral entry? Future Virology 2017;12:569-81. [DOI: 10.2217/fvl-2017-0062] [Reference Citation Analysis]
23 Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE Jr. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. J Virol 2019;93:e01439-18. [PMID: 30728263 DOI: 10.1128/JVI.01439-18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Singleton CD, Humby MS, Yi HA, Rizzo RC, Jacobs A. Identification of Ebola Virus Inhibitors Targeting GP2 Using Principles of Molecular Mimicry. J Virol 2019;93:e00676-19. [PMID: 31092576 DOI: 10.1128/JVI.00676-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
25 Papageorgiou AC, Mohsin I. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Cells 2020;9:E2343. [PMID: 33105869 DOI: 10.3390/cells9112343] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
26 Quinlan DS, Raman R, Tharakaraman K, Subramanian V, Del Hierro G, Sasisekharan R. An inter-residue network model to identify mutational-constrained regions on the Ebola coat glycoprotein. Sci Rep 2017;7:45886. [PMID: 28397835 DOI: 10.1038/srep45886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
27 Brannan JM, He S, Howell KA, Prugar LI, Zhu W, Vu H, Shulenin S, Kailasan S, Raina H, Wong G, Rahim MN, Banadyga L, Tierney K, Zhao X, Li Y, Holtsberg FW, Dye JM, Qiu X, Aman MJ. Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates. Nat Commun 2019;10:105. [PMID: 30631063 DOI: 10.1038/s41467-018-08040-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
28 Tran EE, Nelson EA, Bonagiri P, Simmons JA, Shoemaker CJ, Schmaljohn CS, Kobinger GP, Zeitlin L, Subramaniam S, White JM. Mapping of Ebolavirus Neutralization by Monoclonal Antibodies in the ZMapp Cocktail Using Cryo-Electron Tomography and Studies of Cellular Entry. J Virol 2016;90:7618-27. [PMID: 27279622 DOI: 10.1128/JVI.00406-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
29 Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, Crowe JE Jr, Ward AB. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies. Cell Rep 2021;35:108984. [PMID: 33852862 DOI: 10.1016/j.celrep.2021.108984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
30 Fan P, Chi X, Liu G, Zhang G, Chen Z, Liu Y, Fang T, Li J, Banadyga L, He S, Yu C, Qiu X, Chen W. Potent neutralizing monoclonal antibodies against Ebola virus isolated from vaccinated donors. MAbs 2020;12:1742457. [PMID: 32213108 DOI: 10.1080/19420862.2020.1742457] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Meyer M, Yoshida A, Ramanathan P, Saphire EO, Collins PL, Crowe JE Jr, Samal S, Bukreyev A. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors. Cell Rep 2018;24:1816-29. [PMID: 30110638 DOI: 10.1016/j.celrep.2018.07.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Olukitibi TA, Ao Z, Mahmoudi M, Kobinger GA, Yao X. Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach. Microorganisms 2019;7:E402. [PMID: 31569539 DOI: 10.3390/microorganisms7100402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Kirchoff MC, Pierson JF. Considerations for Use of Investigational Drugs in Public Health Emergencies. Ther Innov Regul Sci 2017;51:146-52. [PMID: 28663940 DOI: 10.1177/2168479016680253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Patel S, Patel S. Analysis of Ebola virus polymerase domains to find strain-specific differences and to gain insight on their pathogenicity. Virusdisease 2016;27:242-50. [PMID: 28466035 DOI: 10.1007/s13337-016-0334-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Di Paola N, Sanchez-Lockhart M, Zeng X, Kuhn JH, Palacios G. Viral genomics in Ebola virus research. Nat Rev Microbiol 2020;18:365-78. [PMID: 32367066 DOI: 10.1038/s41579-020-0354-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
36 Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H, Igarashi M, Yoshida R, Noyori O, Feldmann H, Takada A. Discovery of an antibody for pan-ebolavirus therapy. Sci Rep 2016;6:20514. [PMID: 26861827 DOI: 10.1038/srep20514] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 11.3] [Reference Citation Analysis]
37 Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB. In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. Cell Rep 2018;25:1982-1993.e4. [PMID: 30428362 DOI: 10.1016/j.celrep.2018.10.062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
38 Liu G, Wong G, Su S, Bi Y, Plummer F, Gao GF, Kobinger G, Qiu X. Clinical Evaluation of Ebola Virus Disease Therapeutics. Trends Mol Med 2017;23:820-30. [PMID: 28822631 DOI: 10.1016/j.molmed.2017.07.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
39 Flyak AI, Kuzmina N, Murin CD, Bryan C, Davidson E, Gilchuk P, Gulka CP, Ilinykh PA, Shen X, Huang K, Ramanathan P, Turner H, Fusco ML, Lampley R, Kose N, King H, Sapparapu G, Doranz BJ, Ksiazek TG, Wright DW, Saphire EO, Ward AB, Bukreyev A, Crowe JE Jr. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat Microbiol 2018;3:670-7. [PMID: 29736037 DOI: 10.1038/s41564-018-0157-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
40 Mitchell DAJ, Dupuy LC, Sanchez-Lockhart M, Palacios G, Back JW, Shimanovskaya K, Chaudhury S, Ripoll DR, Wallqvist A, Schmaljohn CS. Epitope mapping of Ebola virus dominant and subdominant glycoprotein epitopes facilitates construction of an epitope-based DNA vaccine able to focus the antibody response in mice. Hum Vaccin Immunother 2017;13:2883-93. [PMID: 28699812 DOI: 10.1080/21645515.2017.1347740] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
41 Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Antibody-mediated protection against Ebola virus. Nat Immunol 2018;19:1169-78. [PMID: 30333617 DOI: 10.1038/s41590-018-0233-9] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 17.8] [Reference Citation Analysis]
42 Gilchuk P, Murin CD, Milligan JC, Cross RW, Mire CE, Ilinykh PA, Huang K, Kuzmina N, Altman PX, Hui S, Gunn BM, Bryan AL, Davidson E, Doranz BJ, Turner HL, Alkutkar T, Flinko R, Orlandi C, Carnahan R, Nargi R, Bombardi RG, Vodzak ME, Li S, Okoli A, Ibeawuchi M, Ohiaeri B, Lewis GK, Alter G, Bukreyev A, Saphire EO, Geisbert TW, Ward AB, Crowe JE Jr. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Immunity 2020;52:388-403.e12. [PMID: 32023489 DOI: 10.1016/j.immuni.2020.01.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
43 Chan SK, Rahumatullah A, Lai JY, Lim TS. Naïve Human Antibody Libraries for Infectious Diseases. Adv Exp Med Biol 2017;1053:35-59. [PMID: 29549634 DOI: 10.1007/978-3-319-72077-7_3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Garry RF. Ebola Mysteries and Conundrums. J Infect Dis 2019;219:511-3. [PMID: 30085161 DOI: 10.1093/infdis/jiy476] [Reference Citation Analysis]
45 Agnolon V, Kiseljak D, Wurm MJ, Wurm FM, Foissard C, Gallais F, Wehrle S, Muñoz-Fontela C, Bellanger L, Correia BE, Corradin G, Spertini F. Designs and Characterization of Subunit Ebola GP Vaccine Candidates: Implications for Immunogenicity. Front Immunol 2020;11:586595. [PMID: 33250896 DOI: 10.3389/fimmu.2020.586595] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhang Q, Gui M, Niu X, He S, Wang R, Feng Y, Kroeker A, Zuo Y, Wang H, Wang Y, Li J, Li C, Shi Y, Shi X, Gao GF, Xiang Y, Qiu X, Chen L, Zhang L. Potent neutralizing monoclonal antibodies against Ebola virus infection. Sci Rep 2016;6:25856. [PMID: 27181584 DOI: 10.1038/srep25856] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
47 Ibeh N, Nshogozabahizi JC, Aris-Brosou S. Both Epistasis and Diversifying Selection Drive the Structural Evolution of the Ebola Virus Glycoprotein Mucin-Like Domain. J Virol 2016;90:5475-84. [PMID: 27009964 DOI: 10.1128/JVI.00322-16] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
48 Ahn WS, Kim TS, Park YJ, Park YK, Kim HD, Kim J. Production, characterization, and epitope mapping of monoclonal antibodies of ribosomal protein S3 (rpS3). Anim Cells Syst (Seoul) 2021;25:323-36. [PMID: 34745438 DOI: 10.1080/19768354.2021.1980100] [Reference Citation Analysis]
49 Howell KA, Qiu X, Brannan JM, Bryan C, Davidson E, Holtsberg FW, Wec AZ, Shulenin S, Biggins JE, Douglas R, Enterlein SG, Turner HL, Pallesen J, Murin CD, He S, Kroeker A, Vu H, Herbert AS, Fusco ML, Nyakatura EK, Lai JR, Keck ZY, Foung SKH, Saphire EO, Zeitlin L, Ward AB, Chandran K, Doranz BJ, Kobinger GP, Dye JM, Aman MJ. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site. Cell Rep 2016;15:1514-26. [PMID: 27160900 DOI: 10.1016/j.celrep.2016.04.026] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 9.8] [Reference Citation Analysis]
50 Khurana S, Fuentes S, Coyle EM, Ravichandran S, Davey RT Jr, Beigel JH. Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies. Nat Med 2016;22:1439-47. [PMID: 27798615 DOI: 10.1038/nm.4201] [Cited by in Crossref: 56] [Cited by in F6Publishing: 53] [Article Influence: 9.3] [Reference Citation Analysis]
51 Cornish JP, Moore IN, Perry DL, Lara A, Minai M, Promeneur D, Hagen KR, Virtaneva K, Paneru M, Buechler CR, O'Connor DH, Bailey AL, Cooper K, Mazur S, Bernbaum JG, Pettitt J, Jahrling PB, Kuhn JH, Johnson RF. Clinical Characterization of Host Response to Simian Hemorrhagic Fever Virus Infection in Permissive and Refractory Hosts: A Model for Determining Mechanisms of VHF Pathogenesis. Viruses 2019;11:E67. [PMID: 30650570 DOI: 10.3390/v11010067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Patel JS, Quates CJ, Johnson EL, Ytreberg FM. Expanding the watch list for potential Ebola virus antibody escape mutations. PLoS One 2019;14:e0211093. [PMID: 30897171 DOI: 10.1371/journal.pone.0211093] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
53 Gilchuk P, Kuzmina N, Ilinykh PA, Huang K, Gunn BM, Bryan A, Davidson E, Doranz BJ, Turner HL, Fusco ML, Bramble MS, Hoff NA, Binshtein E, Kose N, Flyak AI, Flinko R, Orlandi C, Carnahan R, Parrish EH, Sevy AM, Bombardi RG, Singh PK, Mukadi P, Muyembe-Tamfum JJ, Ohi MD, Saphire EO, Lewis GK, Alter G, Ward AB, Rimoin AW, Bukreyev A, Crowe JE Jr. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein. Immunity 2018;49:363-374.e10. [PMID: 30029854 DOI: 10.1016/j.immuni.2018.06.018] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 10.0] [Reference Citation Analysis]
54 Cai Y, Yu S, Chi X, Radoshitzky SR, Kuhn JH, Berger EA. An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells. PLoS One 2021;16:e0245024. [PMID: 33411835 DOI: 10.1371/journal.pone.0245024] [Reference Citation Analysis]
55 Lambe T, Bowyer G, Ewer KJ. A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? Philos Trans R Soc Lond B Biol Sci 2017;372:20160295. [PMID: 28396468 DOI: 10.1098/rstb.2016.0295] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
56 Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir. Viruses 2019;11:E326. [PMID: 30987343 DOI: 10.3390/v11040326] [Cited by in Crossref: 277] [Cited by in F6Publishing: 242] [Article Influence: 92.3] [Reference Citation Analysis]
57 Ripoll DR, Mitchell DAJ, Dupuy LC, Wallqvist A, Schmaljohn C, Chaudhury S. Combinatorial peptide-based epitope mapping from Ebola virus DNA vaccines and infections reveals residue-level determinants of antibody binding. Hum Vaccin Immunother 2017;13:2953-66. [PMID: 28922082 DOI: 10.1080/21645515.2017.1360454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
58 Zhang Y, Wei Y, Li Y, Wang X, Liu Y, Tian D, Jia X, Gong R, Liu W, Yang L. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability. PLoS Negl Trop Dis 2021;15:e0008403. [PMID: 33711011 DOI: 10.1371/journal.pntd.0008403] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Gilchuk P, Guthals A, Bonissone SR, Shaw JB, Ilinykh PA, Huang K, Bombardi RG, Liang J, Grinyo A, Davidson E, Chen EC, Gunn BM, Alter G, Saphire EO, Doranz BJ, Bukreyev A, Zeitlin L, Castellana N, Crowe JE Jr. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma. Front Immunol 2021;12:706757. [PMID: 34335620 DOI: 10.3389/fimmu.2021.706757] [Reference Citation Analysis]
60 Mirza MU, Vanmeert M, Ali A, Iman K, Froeyen M, Idrees M. Perspectives towards antiviral drug discovery against Ebola virus. J Med Virol 2019;91:2029-48. [PMID: 30431654 DOI: 10.1002/jmv.25357] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
61 Miller CR, Johnson EL, Burke AZ, Martin KP, Miura TA, Wichman HA, Brown CJ, Ytreberg FM. Initiating a watch list for Ebola virus antibody escape mutations. PeerJ 2016;4:e1674. [PMID: 26925318 DOI: 10.7717/peerj.1674] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
62 Ruedas JB, Ladner JT, Ettinger CR, Gummuluru S, Palacios G, Connor JH. Spontaneous Mutation at Amino Acid 544 of the Ebola Virus Glycoprotein Potentiates Virus Entry and Selection in Tissue Culture. J Virol 2017;91:e00392-17. [PMID: 28539437 DOI: 10.1128/JVI.00392-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
63 Zhao X, Howell KA, He S, Brannan JM, Wec AZ, Davidson E, Turner HL, Chiang CI, Lei L, Fels JM, Vu H, Shulenin S, Turonis AN, Kuehne AI, Liu G, Ta M, Wang Y, Sundling C, Xiao Y, Spence JS, Doranz BJ, Holtsberg FW, Ward AB, Chandran K, Dye JM, Qiu X, Li Y, Aman MJ. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability. Cell 2017;169:891-904.e15. [PMID: 28525756 DOI: 10.1016/j.cell.2017.04.038] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 14.4] [Reference Citation Analysis]
64 Bixler SL, Duplantier AJ, Bavari S. Discovering Drugs for the Treatment of Ebola Virus. Curr Treat Options Infect Dis 2017;9:299-317. [PMID: 28890666 DOI: 10.1007/s40506-017-0130-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
65 Ruedas JB, Arnold CE, Palacios G, Connor JH. Growth-Adaptive Mutations in the Ebola Virus Makona Glycoprotein Alter Different Steps in the Virus Entry Pathway. J Virol 2018;92:e00820-18. [PMID: 30021890 DOI: 10.1128/JVI.00820-18] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
66 Garza JA, Taylor AB, Sherwood LJ, Hart PJ, Hayhurst A. Unveiling a Drift Resistant Cryptotope within Marburgvirus Nucleoprotein Recognized by Llama Single-Domain Antibodies. Front Immunol 2017;8:1234. [PMID: 29038656 DOI: 10.3389/fimmu.2017.01234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
67 Fuentes S, Ravichandran S, Khurana S. Antibody Repertoire of Human Polyclonal Antibodies Against Ebola Virus Glycoprotein Generated After Deoxyribonucleic Acid and Protein Vaccination of Transchromosomal Bovines. J Infect Dis 2018;218:S597-602. [PMID: 29939294 DOI: 10.1093/infdis/jiy325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Kuzmina NA, Younan P, Gilchuk P, Santos RI, Flyak AI, Ilinykh PA, Huang K, Lubaki NM, Ramanathan P, Crowe JE Jr, Bukreyev A. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors. Cell Rep 2018;24:1802-1815.e5. [PMID: 30110637 DOI: 10.1016/j.celrep.2018.07.035] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
69 Bhatia B, Furuyama W, Hoenen T, Feldmann H, Marzi A. Ebola Virus Glycoprotein Domains Associated with Protective Efficacy. Vaccines (Basel) 2021;9:630. [PMID: 34200548 DOI: 10.3390/vaccines9060630] [Reference Citation Analysis]
70 Gaudinski MR, Coates EE, Novik L, Widge A, Houser KV, Burch E, Holman LA, Gordon IJ, Chen GL, Carter C, Nason M, Sitar S, Yamshchikov G, Berkowitz N, Andrews C, Vazquez S, Laurencot C, Misasi J, Arnold F, Carlton K, Lawlor H, Gall J, Bailer RT, McDermott A, Capparelli E, Koup RA, Mascola JR, Graham BS, Sullivan NJ, Ledgerwood JE; VRC 608 Study team. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet 2019;393:889-98. [PMID: 30686586 DOI: 10.1016/S0140-6736(19)30036-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 29] [Article Influence: 20.3] [Reference Citation Analysis]
71 Howell KA, Brannan JM, Bryan C, McNeal A, Davidson E, Turner HL, Vu H, Shulenin S, He S, Kuehne A, Herbert AS, Qiu X, Doranz BJ, Holtsberg FW, Ward AB, Dye JM, Aman MJ. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus. Cell Rep 2017;19:413-24. [PMID: 28402862 DOI: 10.1016/j.celrep.2017.03.049] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 9.4] [Reference Citation Analysis]